Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

NCT00844597 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: AVI-4658 for Injection

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]